Pierre Bougnères
Université Paris-Saclay
5 Papers
7 Citations
Pierre Bougnères is an academic researcher from Université Paris-Saclay. The author has contributed to research in topics: Placebo & Adrenal cortex. The author has an hindex of 2, co-authored 5 publications.
Chat about Author
Papers
Exploring the risk of hypospadias in children born from mothers living close to a vineyard.
Pierre Bougnères,Raphaël Porcher,Laure Esterle,David Baker,Adrien de la Vaissière,Sofia Meurisse,Sophie Valtat,Anne-Laure Castell,Pierre Mouriquand,Alain-Jacques Valleron +9 more
TL;DR: In this paper, the authors found that children born to mothers living close to a vineyard have a two-fold increased risk of Hypospadias (H) compared to those who live far away from vineyards.
Correction of a knock-in mouse model of acrodysostosis with gene therapy using a rAAV9-CAG-human PRKAR1A vector
Yasemin Özgür-Günes,Catherine Le Stunff,Malha Chedik,Marie-Pierre Belot,Pierre-Hadrien Becker,Véronique Blouin,Pierre Bougnères +6 more
TL;DR: In this article, the effects of a rAAV9-CAG-human PRKR1A (hPRKAR1A) vector intravenously administered at 4 weeks of age were tested.
5
An AAVrh10-CAG-CYP21-HA vector allows persistent correction of 21-hydroxylase deficiency in a Cyp21−/− mouse model
TL;DR: The adrenal tropism of AAVrh10 and the persistent correction of phenotypic and biochemical traits in Cyp21−/− mice pave a first step on the way to GT of 21OHD in humans.
Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study.
Michelle Rosenzwajg,Randa Salet,Roberta Lorenzon,Nicolas Tchitchek,Alexandra Roux,Claude Bernard,Jean-Claude Carel,Caroline Storey,Michel Polak,Jacques Beltrand,Chloé Amouyal,Agnès Hartemann,Pierre Corbeau,Eric Vicaut,Cecile Bibal,Pierre Bougnères,Tu-Anh Tran,David Klatzmann +17 more
TL;DR: The safety profile at all doses, the dose-dependent effects on Tregs and the observed variability of the Treg response to ld-IL2 in children with newly diagnosed type 1 diabetes call for use of the highest dose in future developments.